A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseA practical algorithm for managing Alzheimer's disease: what, when, and why?Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsDementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Third degree atrioventricular block associated with treatment with rivastigmine transdermal patchA pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative.Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditionsAddressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trialsSingle dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteersPredictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice.Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease.A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's DiseaseReal-world evaluation of compliance and preference in Alzheimer's disease treatment.Alzheimer's disease and its treatment with a novel transdermal patch therapy: survey of caregiver experiencesAlzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan.Present and prospective clinical therapeutic regimens for Alzheimer's disease.A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Relative tolerability of Alzheimer's disease treatmentsRivastigmine in Parkinson's disease dementia.Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.
P2860
Q24186551-97FCCD3E-9CE6-49D6-9950-14761C5175DFQ24187067-44C0F7B5-86B1-4E28-820F-B842C2F75817Q24241686-CC792309-F408-462E-94C5-2562B42338D0Q26859831-800758A6-F234-4A31-9D4B-2F3AC3F59C01Q26863383-CC80E72E-6C45-497F-BBD4-87BFC60A75B4Q26997299-469665B9-B04C-4A1F-B6E4-499BB34D6D61Q33160127-DA96AEB1-403B-4C95-8A9B-6EEB7014FA82Q33162691-17BF9A0F-971E-40A8-89AB-2AA99C9CE9C2Q33370687-1068EE4D-F97B-481F-9E74-4936FB53FE25Q33596451-A3911F5D-948E-48A3-9108-3DDB72205E96Q33937187-E717CE4B-6A82-4BC8-9053-7215BC3A5B3FQ34032505-B6286833-6DD4-430D-A7E6-60FE29AD6EEAQ34051079-6FD43A59-0151-4301-99B7-88FD9CB42A87Q34306253-A62775C8-3C03-4E50-A09A-CC3BDB00F435Q34487826-E7AF153B-3987-4D98-B7A2-C5C262132BD6Q34521949-D0DF3B36-9BDC-42A0-AA7C-CD147FEFE088Q34542646-C30E3649-EB35-45CB-B43C-99CDD5D5D6D2Q34543707-9D476ACD-EC5F-45B8-ACDA-C44C8691A7C3Q35184995-89750C60-FD20-4DFB-9C30-256D1E4FEC15Q35252005-3D24E3F0-FA93-463C-8F0C-8A3E799F8A7CQ35428213-17F7B710-E9B3-41D0-AA6C-62E18DB1B9FFQ35905814-29CBB967-D25D-4E8B-ABBA-64ED827A00C7Q35988441-C7EB5D24-318E-40FF-8638-38F9170AA383Q36165980-3652D448-3D81-450E-AAB4-BA4A791C0975Q36261229-DD6798F4-C1FF-4A48-84CE-3B37964786C3Q36264977-C9517138-00CE-42FA-9389-186EB63E6A27Q36419735-D4EE68C7-5973-41EA-89E3-89CF5E1BC210Q36467267-20F80120-B375-42F1-85E4-4F61750C8FCEQ36538811-C14AF73C-D878-48F2-8DBF-E6D56B707704Q36766861-01152995-2A2E-41CF-B22E-91A3E9CC894BQ36876447-164EDE04-FE4A-4A0E-9841-151076F79E42Q36998823-38E0A3DC-4C1D-4C3D-B70C-B2E288C0063CQ37070395-B6D1F7B7-C58C-427C-831E-3B4ADF9ACAF8Q37193026-C0AA6845-772C-45E2-B4C1-46CEEF845F91Q37225818-008FCC75-D02E-45DF-9E0A-98BB5588E7DBQ37232006-D0D08B6D-AD12-4C33-9C27-9B6DA3551CEBQ37255114-1A06E864-6102-4634-AAD2-3C1350D08CF4Q37325828-B2C91AD4-36FF-40D2-A270-EBF4A661F5FDQ37358548-62A02D9F-1DF3-40C8-A29A-A6FFD081C989Q37385577-0700B61A-912A-4A9E-B25A-85A0BCAC2A76
P2860
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule
description
im Jahr 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2007
@uk
name
A six-month double-blind, rand ...... vastigmine patchversus capsule
@en
A six-month double-blind, rand ...... vastigmine patchversus capsule
@nl
type
label
A six-month double-blind, rand ...... vastigmine patchversus capsule
@en
A six-month double-blind, rand ...... vastigmine patchversus capsule
@nl
prefLabel
A six-month double-blind, rand ...... vastigmine patchversus capsule
@en
A six-month double-blind, rand ...... vastigmine patchversus capsule
@nl
P2093
P2860
P356
P1476
A six-month double-blind, rand ...... vastigmine patchversus capsule
@en
P2093
Carl Sadowsky
George Grossberg
Jennifer Nagel
Marco Onofrj
Niels Andreasen
Roger Lane
Stefanie Zechner
P2860
P304
P356
10.1002/GPS.1788
P407
P577
2007-01-01T00:00:00Z